Multiple myeloma cell surface antigen

Multiple myeloma cell surface antigens are a heterogeneous group of membrane-bound proteins and glycoproteins that are expressed on malignant plasma cells in multiple myeloma. These include, but are not limited to, CD38, CD138 (syndecan-1), CD269 (BCMA/TNFRSF17), SLAMF7 (CS1), and, in some settings, CCR10 and others. These surface antigens serve as crucial diagnostic biomarkers, have biological roles in cell signaling, adhesion, and immune evasion, and represent key therapeutic targets for monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and CAR-T cell therapies. The specific antigen profile of myeloma cells can show both inter- and intra-patient heterogeneity and may change with disease progression and therapy. The diversity of surface antigens enables multi-targeted therapeutic strategies, but also poses challenges for specificity and resistance[1][2][3].

Other names

Myeloma-associated cell surface proteinMyeloma immunotherapy targetPlasma cell surface antigen (in the context of multiple myeloma)

Monoclonal antibody-mediated cell killing (e.g., cytotoxicity, antibody-dependent cellular cytotoxicity) CAR-T or bispecific T-cell engagers mediating targeted T-cell cytotoxicity Antibody-drug conjugate-mediated delivery of cytotoxic payload